Medicxi
Overview
Medicxi is a European life sciences venture capital firm specializing in early-stage investments in biotechnology and pharmaceutical companies across Europe and the United States. The firm focuses on creating and investing in companies along the full drug development continuum, from early discovery to late-stage therapeutics. Medicxi's mission is to address unmet medical needs by supporting innovative drug hunters and entrepreneurs in developing transformative therapies for patients. The firm's investment strategy is centered around an 'asset-centric' model, emphasizing the development of specific therapeutic assets rather than broad platform technologies. This approach has led to the creation of 16 new companies since its previous fundraise, including Ottimo Pharma and Curevo Vaccine. Notable exits from the portfolio include Vicebio, acquired by Sanofi for $1.6 billion, and Versanis Bio, acquired by Eli Lilly for $1.9 billion. Medicxi's team comprises professionals with extensive scientific, medical, and operational experience, having invested in over 89 innovative biopharma companies and achieved 32 exits through IPO and M&A. The firm has raised multiple funds, with the most recent being Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The firm's investors include global pharmaceutical companies such as GlaxoSmithKline, Johnson & Johnson Innovation, Novartis, and Verily (an Alphabet company).
Investment Focus
- Focus on life sciences sector
- Clear product vision addressing unmet medical needs
- Early and late-stage therapeutics
- Alignment with Medicxi's 'asset-centric' investment model
- Innovative biotechnology companies with clear product visions
- Focus on transformative therapies addressing unmet medical needs
- Early-stage companies across Europe and the United States
Portfolio Companies
Reach Medicxi directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Medicxi
What sectors does Medicxi invest in?
Medicxi invests in Healthcare, Digital Health, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in London, England, United Kingdom. Medicxi is listed as a venture capital in the ConnectSafely investor database.
What stage does Medicxi invest at?
Medicxi backs companies at Pre-Seed, Seed, Early Stage, Series A, Series B and Growth, writing cheques of 3M - 50M.
Which regions does Medicxi invest in?
Medicxi invests across United States, United Kingdom, Germany, France, Italy and Denmark.
Who are the partners at Medicxi?
Team members listed for Medicxi include Richard Lee (Co-Founder and Operating Partner) and Giuseppe Zocco (Co-Founder and Partner).
What companies has Medicxi invested in?
Medicxi's portfolio includes Centessa Pharmaceuticals, PanGenetics, Molecular Partners, Minerva Biosciences, Villaris Therapeutics, MiroBio, Versanis Bio and Abivax.
How do I contact Medicxi?
Medicxi's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
